Overview

A Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer

Status:
Not yet recruiting

Trial end date:
2029-08-01

Target enrollment:

Participant gender:

Summary

Randomized non-comparative phase II trial to assess the preliminary signs of antitumor activity of darolutamide plus radiation therapy in patients with unfavorable intermediate risk prostate cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Institut Bergonié

Collaborator:

Bayer